Skip to search formSkip to main contentSkip to account menu

XR5944

Known as: XR 5944 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Phenazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.
XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can… 
2015
2015
Abstract 2445: DNA recognition by XR5944, a novel bis-intercalator and potent anticancer drug
DNA is a major target for drugs used in cancer therapy. However, DNA interactive chemotherapeutics are limited by adverse effects… 
2014
2014
Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator
XR5944, a deoxyribonucleic acid (DNA) bis-intercalator with potent anticancer activity, can bind the estrogen response element… 
2011
2011
Intercalation of XR5944 with the estrogen response element is modulated by the tri-nucleotide spacer sequence between half-sites
2011
2011
Abstract B66: Characterization of bis-phenazine compounds that inhibit estrogen signaling through direct interaction with estrogen response elements
Hormone therapies interfere with estrogen signaling by targeting Estrogen Receptors (ERs) and are routinely used for the… 
2009
2009
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases
PurposePrevious in vitro cleavage data showed that XR11576 and XR5944 stabilised topoisomerase I and topoisomerase II complexes… 
2007
2007
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944
The substituted phenazines XR11576 and XR5944 were originally described as dual topoisomerase-I/II poisons. Subsequent reports… 
2007
2007
XR5944: A potent inhibitor of estrogen receptors
The anticancer drug XR5944 was originally developed as a topoisomerase inhibitor and was subsequently shown to be a transcription… 
2005
2005
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity… 
2004
2004
Initial phase I study of XR5944, a novel DNA and RNA targeting agent.
2100 Background: XR5994 (MLN944) is a novel DNA/RNA targeting agent with a mechanism of action distinct from that of currently… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)